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Generation of hybridomas expressing TCRs from human T cell clones. 
Complete TCRs were introduced into the human CD4+ mouse recipient hybridoma cell line 
54ζ (1). Three DNA fragments were generated for each TCR: two synthesized fragments (IDT 
DNA) encoding the variable domains of the TCR α- and β-chains of each T cell clone, and a 
purified PCR product encoding the murine Cα domain connected to the porcine teschovirus-1 2A 
peptide. These fragments possessed homologous overlapping nucleotide sequences allowing 
cloning in the proper orientation into a murine stem cell virus (MSCV)-based retroviral vector 
using a Gibson Assembly method (New England Biolabs). MSCV plasmids encoding full-length 
chimeric TRA and TRB genes separated by the 2A peptide cleavage site were packaged as 
retrovirus by transient transfection of Phoenix 293T cells. Retroviral transduction with viral 
supernatants, flow-sorting for TCR and CD4 expression, and maintenance of cell lines in culture 
were as previously described (2).   
 
T cell hybridoma activation assays. 
T cell hybridomas and either HLA-DP2 transfected fibroblasts (3) or B cells harvested from 
HLA-DP2 Tg mice (4) were incubated overnight with BeSO4 (75-200 M) and positional 
scanning library (PSL) mixtures (20-200 g/ml) or peptides as previously described (2, 3). All 
assays were done in OptiPRO serum-free medium (Gibco, ThermoFisher) supplemented with 
0.5% FBS (Hyclone). Testing of individual crude peptides was performed at 0.5, 5, and 50 
µg/ml, and for dose response curves, peptide concentrations ranged from 0.1 nM to 10 µM. 
Recombinant CCL3 and CCL4 proteins (Peprotech) were tested in triplicate at 0.3 - 20 g/ml in 




For all experiments, supernatants were harvested after 22-24 hours incubation, and mouse IL-2 
was measured by ELISA (eBioscience). In dosing experiments, the concentration of peptide that 
generated 50% of the maximum IL-2 response (EC50) for each hybridoma was determined using 
nonlinear regression (sigmoidal-fit; Prism, GraphPad Software). 
 
Positional scanning libraries and peptides. 
T cell hybridomas expressing selected TCRs were first screened for responses against an 
unbiased decapeptide PSL (3, 5, 6). PSLs are comprised of 200 mixtures synthesized in an OX9 
format, where O represents a specific amino acid at a defined position and X represents an 
equimolar mixture of 19 natural amino acids (except cysteine) in each of the remaining 9 
positions. A biased decapeptide PSL was also designed such that all peptides in each mixture 
were composed of a D at position 5 and an E at position 8 of the peptide (D5E8 PSL). Individual 
peptides were synthesized using the PEPScreen 96-well array (Sigma-Aldrich). Peptides chosen 
for further study were synthesized at 95% purity (CPC Scientific).  
 
Scoring matrices and database searches. 
Multiple scoring matrices were generated by assigning numerical values to the stimulatory 
potency of defined amino acids at each position of the decapeptide D5E8 PSL. For each 
hybridoma, two matrices were generated using the value of IL-2 (pg/ml) in the presence of 
peptide mixtures/Be and the logarithm of that value. For the two defined positions (D5E8), the 
minimum value of each matrix was assigned to all amino acids except for the amino acid fixed at 
that position (i.e., D at position 5, E at position 8). The value for these amino acids was assigned 
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the maximum stimulatory potency measured among all the mixtures at all positions.  For 
hybridomas tested at multiple dose points (8845-c3 and 8133-c4r), each dose was used 
independently, and interpolated ED300 (the dose to reach 300 pg/ml) values were generated. A 
third matrix consisting of  values was also used. Finally, the four hybridoma matrices 
generated from testing at 50 μg/ml were normalized to a maximum value of 1000 pg/ml and 
added together to create composite activity matrices using these values and the logarithm of 
these values. The predicted stimulatory potential of a peptide, or score, was calculated by 
summing the matrix values associated with each amino acid in each position of the peptide. The 
sum of the maximum values at each position was defined as the maximum matrix score. The 
scoring matrix was applied to rank, according to their stimulatory score, all of the overlapping 
peptides within each protein sequence of a human Uniprot protein database (downloaded 
7/2/2018), as previously described (5, 7). 
 
ELISA for CCL3 and CCL4 secretion by CBD BAL cells 
BAL cells (1 x 106 cells/ml) from CBD patients were in placed in culture in 96 well U-bottomed 
plates (5 wells/condition) in medium alone or 100 M BeSO4. After 48 hours incubation, 
supernatants were pooled, cleared of cellular debris and stored at -80C. Human CCL3 and 
CCL4 chemokines were assessed by ELISA (Invitrogen), and results are presented as the average 
of duplicate wells.  
 
Tetramer staining and dual intracellular interferon-/tetramer assay. 
Beryllium-saturated MHCII tetramers with covalently attached peptides were made using a 
baculovirus expression system (3, 8), and an HLA-DP2-CLIP tetramer was provided by the NIH 
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Tetramer Core Facility at Emory University (Atlanta, GA). Hybridoma cells matched for 
expression of high levels of TCR were stained with HLA-DP2–CCL3/Be, DP2–CCL4/Be, DP2-
PLXNA4/Be or DP2-CLIP tetramers (20 µg/ml) as previously described (3). 
 
For dual assessment of IFN-γ expression and HLA-DP2-tetramer binding, BAL cells were 
stimulated with medium or BeSO4 (100 µM) for 6 h prior to tetramer staining. Cells were stained 
for surface markers and then fixed, permeabilized, and stained with anti–IFN-γ–PE-Cy7 (B27; 
BD Biosciences) mAb for 30 min. Cell staining was evaluated on a FACSCanto II flow 
cytometer (BD Biosciences), and data were analyzed with FlowJo software (Tree Star). CD3+, 
CD4+ T cells were analyzed for tetramer binding and cytokine expression using no stimulation 
and HLA-DP2-CLIP tetramer staining to set gates. 
 
HLA-DP2 Tg and LKGGG CDR3 TCR retrogenic HLA-DP2 Tg mice. 
HLA-DP2 Tg C57BL/6 mice were housed and bred at the University of Colorado Biological 
Resource Center. C57BL/6 RAG-/- mice were purchased from The Jackson Laboratory and bred 
to express HLA-DP2. Mice were used at 6-8 weeks of age.  
 
To generate HLA-DP2 Tg C57BL/6 mice TCR retrogenic mice, Phoenix cells were 
cotransfected with TCR-encoding MSCV vectors and the pCL-Eco packaging plasmid using 
Lipofectamine 2000 (Invitrogen) to produce replication-incompetent retroviruses encoding TCR 
genes. High-titer viral supernatants were collected after 24 hours from large-scale transfections 
and stored at -80C for use in multiple experiments. For retroviral-mediated transfer of TCR 
genes (9, 10), bone marrow cells were extracted from femurs of HLA-DP2 Tg RAG-/- B6 mice. 
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Purified hematopoietic progenitor cells (Stemcell) were placed in culture for 48 hours in DMEM 
supplemented with 20% FBS (Hyclone) and a cytokine cocktail (all from Peprotech) containing 
IL-3 (20 ng/ml), IL-6 (50 ng/ml) and mouse stem cell factor (50 ng/ml). Stem cells were 
transduced with viral supernatant on successive days by spinfection at 37C for 2 hours at 2500 
rpm with retroviral supernatant, polybrene (7.5 g/ml) and freshly added cytokines. Cells were 
expanded in culture 72 hours to maximize the yield and percentage of GFP+ (i.e., virally-
transduced) cells. Mice received 15-20 x 106 cells by intravenous injection and were bled for 
TCR reconstitution starting week 5 post-transplantation. Mice typically began the standard 
protocol of Be exposure at 6 weeks after injection of bone marrow-transduced cells. 
 
Mice were exposed to BeO oropharyngeal aspiration using a sensitization/boost protocol as 
previously described (4, 11). At sacrifice on day 21, single cell suspensions of lung cells, BAL 
cells and fluid were collected for analysis. Flow cytometry, IFN-γ ELISPOTs, lung injury 
assessment, and immunohistochemistry of paraffin-embedded lung tissue were performed as 
described (11). BAL was completed using 1 ml of sterile PBS, and CCL4 and CCL3 chemokines 
were assessed in fluid by ELISA (R & D Systems). 
 
For LPS exposure experiments, HLA-DP2 Tg FVB/N mice were exposed to BeO using our 
standard sensitization/boost protocol with and without a single dose of LPS (10 μg; ENZO Life 
Sciences, USA) by oropharyngeal aspiration on day 14. BAL fluid was obtained from sacrificed 
mice after 24 hours to measure CCL4 and CCL3 in BAL fluid, and additional mice were 
sacrificed at day 21 to assess other parameters of disease progression as described above (11). To 
quantitate mononuclear cell infiltrates, whole slide imaging was performed on H&E stained lung 
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sections cut from formalin fixed paraffin embedded tissue. Pyramidal tiff files were analyzed 
using OuPath software (v.0.2.3). Briefly, stain vectors values were automatically determined and 
cells were counted by adjusting the cell detection threshold to maximize the difference between 
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CBD 1041 T cell line abTCRs = 37 (16x y-pixel scale)
AV AJ BV BJ
CBD 1435 T cell line abTCRs = 41 (15x y-pixel scale)
AJ AV BV BJ
CBD 3421 T cell line abTCRs = 71 (8x y-pixel scale)
AJ AV BV BJ
CBD 1234 ex vivo abTCRs = 76 (8x y-pixel scale)
AV AJ BV BJ
CBD 8133 ex vivo abTCRs = 78 (8x y-pixel scale)
AV AJ BV BJ
CBD 8845 ex vivo abTCRs = 58 (10x y-pixel scale)
AJ AV BJ BV
CBD 6092 ex vivo abTCRs = 65 (9x y-pixel scale)
AJ AV BJ BV
Figure S1. Cord diagrams of TR gene segment usage of individual CBD patient’s T cells. 
Cord diagram of gene segment usage of T cells from all CBD patients combined (n = 426 T 
cells). Each individual T cell’s TR gene segment usage (BV, BJ, AV, AJ) is connected by a 
curved line whose thickness is proportional to the number of T cells with the respective gene 
pairing. Genes are color-coded based on frequency of usage, and observed enrichment of 
some gene segments relative to a background naïve repertoire is indicated by arrows. The 
number of complete αβTCRs obtained for each patient is indicated at the top of each plot.
Figure S2
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Figure S2. Beryllium and HLA-DP2 specificity of LKGGG CDR3b-expressing T cell 
hybridomas. (A) Equal numbers of hybridoma cells (from CBD patients 8845 and 8133) and 
HLA-DP2-expressing fibroblasts were mixed with solutions of metal cations (0.2, 2.0, 20 and 
200 µM). IL-2 secretion by hybridomas was measured by ELISA after 22 hours of culture.  
Data are presented as IL-2 release (mean ± SD pg/ml) for the single concentration of cation 
providing a maximal response. (B) DAP3.L fibroblast cells transfected with the indicated 
HLA-DP molecule were mixed with equal numbers of hybridoma cells and placed in culture 
in the presence of BeSO4 (100 µM). IL-2 secretion was measured by ELISA after 22 hours of 
culture, and data are presented as mean IL-2 ± SD (pg/ml) release. Both (A) and (B) are 
representative of two experiments done in triplicate.













































































































































Figure S3. IL-2 response of BAL-derived LKGGG CDR3β TCRs against an unbiased 
decapeptide PSL. Equal numbers of hybridoma cells (8133-c4r and 8845-c3) and DP2.21 
antigen-presenting cells were mixed with BeSO4 (75 µM) and peptide mixtures (200 µg/ml) 
from an unbiased PSL. IL-2 secretion was measured by ELISA after 22 hours of culture. Each 
panel shows results from a scan of an individual peptide position with the x-axis denoting the 
amino acid (single letter code) fixed at each defined position. Data are representative of two 
experiments for each hybridoma performed in duplicate.
Figure S4














































































































Figure S4. IL-2 response of BAL-derived LKGGG CDR3β TCRs against a biased D5E8 
decapeptide PSL. Equal numbers of hybridoma cells (8133-c4r, 8845-c3, 8133-c4 and 8845-
c3r) and DP2.21 antigen-presenting cells were mixed with BeSO4 (75 µM) and peptide 
mixtures (50 µg/ml) from a biased PSL containing a fixed aspartic acid (D) at position 5 and a 
fixed glutamic acid (E) at position 8. IL-2 secretion was measured by ELISA after 22 hours of 
culture. Data were normalized for each hybridoma against the mixture which evoked the 
highest IL-2 release for that hybridoma (F2 for 8133-c4r; F7 for others) and presented as 
stacked bars. Each panel shows results of a scan of an individual peptide position. Data are 
representative of two experiments for each hybridoma completed in duplicate.































8845-c3 8845-c3r 8133-c4 8133-c4r
TD05 V F R I D Y F E S I 89.2 24.7 151.4 16.9
TD13 V F V I D Y F E S I 49.2 31.9 74.7 37.2
TD21 W F R I D Y F E S I 17.5 17.9 119.7 20.5




W F R F D Y F E S I
V V I L W
p1 p2 p3 p4 p5 p6 p7 p8 p9 p10 8845-c3 8845-c3r 8133-c4 8133-c4r
TD01 VFRFDYFESI V F R F D Y F E S I 6 1074 2 1037
TD02 VFRFDYFEWI V F R F D Y F E W I 311 1081 0 832
TD03 VFRFDYLESI V F R F D Y L E S I 1 1154 2 920
TD04 VFRFDYLEWI V F R F D Y L E W I 708 1071 1 814
TD05 VFRIDYFESI V F R I D Y F E S I 1176 1079 1193 909
TD06 VFRIDYFEWI V F R I D Y F E W I 1146 1079 5 620
TD07 VFRIDYLESI V F R I D Y L E S I 1208 1098 2 856
TD08 VFRIDYLEWI V F R I D Y L E W I 1186 967 1 571
TD09 VFVFDYFESI V F V F D Y F E S I 1146 1138 31 976
TD10 VFVFDYFEWI V F V F D Y F E W I 1233 1003 1 755
TD11 VFVFDYLESI V F V F D Y L E S I 1216 1057 1 888
TD12 VFVFDYLEWI V F V F D Y L E W I 1277 932 1 804
TD13 VFVIDYFESI V F V I D Y F E S I 1120 1067 1194 841
TD14 VFVIDYFEWI V F V I D Y F E W I 907 956 11 532
TD15 VFVIDYLESI V F V I D Y L E S I 1071 1097 33 791
TD16 VFVIDYLEWI V F V I D Y L E W I 689 722 1 413
TD17 WFRFDYFESI W F R F D Y F E S I 2 1067 0 931
TD18 WFRFDYFEWI W F R F D Y F E W I 1119 1007 1 688
TD19 WFRFDYLESI W F R F D Y L E S I 1 1089 1 826
TD20 WFRFDYLEWI W F R F D Y L E W I 1111 894 1 460
TD21 WFRIDYFESI W F R I D Y F E S I 1188 1059 1013 821
TD22 WFRIDYFEWI W F R I D Y F E W I 1002 828 1 237
TD23 WFRIDYLESI W F R I D Y L E S I 1103 994 1 660
TD24 WFRIDYLEWI W F R I D Y L E W I 949 614 1 210
TD25 WFVFDYFESI W F V F D Y F E S I 1179 1099 59 931
TD26 WFVFDYFEWI W F V F D Y F E W I 1228 951 1 870
TD27 WFVFDYLESI W F V F D Y L E S I 1192 1088 1 867
TD28 WFVFDYLEWI W F V F D Y L E W I 1202 1005 1 743
TD29 WFVIDYFESI W F V I D Y F E S I 1103 1069 1213 846
TD30 WFVIDYFEWI W F V I D Y F E W I 880 947 84 635
TD31 WFVIDYLESI W F V I D Y L E S I 1045 1085 73 838






Figure S5. Identification of mimotopes that stimulate hybridomas expressing the 
LKGGG CDR3β motif. (A) List of potential mimotopes, chosen based on selection of amino 
acids at each peptide position (shown at top of Figure) having the most stimulatory activity in 
the biased D5E8 PSL in the presence of BeSO4. Hybridoma response to peptides tested at 1 
µg/ml with BeSO4 are shown with activity depicted by color-coding (green, high; yellow, 
moderate; orange, negative). Red bolding (I4, F7, S9) highlights amino acids allowing 
hybridoma 8133-c4 recognition of peptides. (B) Peptide dose-response curves for hybridoma 
8133-c4 evaluating peptides that induced activity in all 4 T cell hybridomas. Equal numbers 
of 8133-c4 hybridoma cells and DP2.21 antigen-presenting cells were mixed with BeSO4 (75 
µM) and peptide, and IL-2 secretion was measured by ELISA after 22 hours of culture. Data 
is plotted as the percentage of maximum IL-2 secretion against peptide concentration. EC50 
values, defined as the concentration of peptide that induces a half-maximal response, are 
listed. (C) Summary of EC50 values for each mimotope that stimulated the 4 Be-specific 
hybridomas, calculated from their respective dose-response curves is shown. Data are 
representative of two separate experiments done in duplicate.



































































































Figure S6. CCL4 peptide dose-response curves. Dose-response curves to pure CCL4 
peptides with single alanine substitutions are shown for hybridomas 8845-c3 (top, left), 8133-
c4 (top, right) and 8133-c4r (bottom, left). Equal numbers of hybridoma cells and DP2.21 
antigen-presenting cells were mixed with BeSO4 (75 µM) and highly-purified CCL4 peptides 
with single alanine substitutions. IL-2 secretion was measured by ELISA after 22 hours of 
culture, and data are plotted as the percentage of maximum IL-2 secretion against peptide 
concentration in the presence of BeSO4. The natural CCL4 peptide (WT) curve is drawn in 
red. EC50 values (nM) for each peptide are displayed in Figure 4B, and data are 
representative of two experiments.
Hyb ID AV AJ BV BJ Freq
8845-c1 21 CA V NDRG S T LG R L Y F G 18 7-2 C A S S L K L AGG I V V T G E L F F 2-2 6/78
8845-c2 38-1 C A F MT E YG NK L V F G 47 7-2 C A S S P GGGG K I Y EQ Y F G 2-7 5/78
1435-c1r 27 C AGG AS S NT G K L I F G 37 18 CA S S P S G D AYG Y T F 1-2 1/103
3421-c2r 13-1 C A A SQ L T GGG NK L T F G 10 6-5 C A S SQ D R E RS Y EQ Y F 2-7 1/106





10mer 1 2 3 4 5 6 7 8 9 10 8845-c1 8845-c2 1435-c1r 3421-c2r
BA001 NFVVDYYETS N F V V D Y Y E T S 745.9 - - 5.3 Q8NHW4|CC4L C-C motif chemokine 4-like
BA002 NFIADYFETS N F I A D Y F E T S 755.4 - - 0.4 P10147|CCL3 C-C motif chemokine 3
BA003 FFRYDFFERI F F R Y D F F E R I 7.0 2.5 1.0 2.2
BA004 LFVIDSFEEL L F V I D S F E E L 1.1 - 0.4 4.5
BA005 YFRVDFYEAM Y F R V D F Y E A M 618.4 - 1.0 - Q5I0X7|TTC32 Tetratricopeptide repeat protein 32
BA006 ARVFDYFEGA A R V F D Y F E G A 244.6 0.2 4.5 0.4 Q9UPN6|SCAF8 Protein SCAF8
BA007 KFVDDLFETI K F V D D L F E T I 736.3 - - - Q9HCM2|PLXA4 Plexin-A4
BA008 QLVVDWLESI Q L V V D W L E S I 756.8 - - - P57740|NU107 Nuclear pore complex protein Nup10
BA009 HFILDFYEKV H F I L D F Y E K V 0.4 - - 16.8
BA010 NLVDDYFELV N L V D D Y F E L V - - - -
BA014 DFIYDLFEHV D F I Y D L F E H V 761.2 0.2 - - Q9HD67|MYO10 Unconventional myosin-X
BA016 FFRNDFLEVV F F R N D F L E V V 1.9 - - -
BA017 LFTFDLIESV L F T F D L I E S V 790.1 - - - Q92990|GLMN Glomulin
BA019 LFIIDGFEEI L F I I D G F E E I 1.7 - - -
BA020 YLVFDFCEHD Y L V F D F C E H D 3.5 0.8 - 0.7
BA022 LFVLDYREAH L F V L D Y R E A H 0.4 0.2 - -
BA023 YLVADYLEFQ Y L V A D Y L E F Q - - - -
BA027 TYRLDVLEAV T Y R L D V L E A V - - 0.4 -
BA029 VFIVDDFESF V F I V D D F E S F 8.6 0.6 1.3 1.6
BA030 WFVYDYSEPA W F V Y D Y S E P A - - - -
BA031 WFIGDWLECS W F I G D W L E C S 198.5 - - - Q9UKP5|ATS6 A disintegrin and metalloproteinase with thrombospondin motifs 6
BA032 QCIADFLEYM Q C I A D F L E Y M 1.5 1.9 2.5 1.0
BA034 LCLIDYYESK L C L I D Y Y E S K 24.7 - 3.4 -
BA035 QLGFDFFEAS Q L G F D F F E A S 0.2 - - -
BA037 YFVLDTSESV Y F V L D T S E S V 1.1 1.7 3.9 2.8
BA038 FIKDDYLETI F I K D D Y L E T I 93.0 3.9 2.8 6.9
BA039 QCKFDLLEEL Q C K F D L L E E L - 9.7 - 21.1
BA044 TFPIDFFEHN T F P I D F F E H N 0.4 - 1.9 -
BA045 ICVADPFEVT I C V A D P F E V T - 2.6 1.6 14.6
BA048 NYIYDLLEEV N Y I Y D L L E E V 393.3 - - - Q02241|KIF23 Kinesin-like protein KIF23
BA051 FFVLDTSESV F F V L D T S E S V - - - 9.6
BA053 ELIFDFFEED E L I F D F F E E D - - - 9.9
BA058 LTVLDFFEGS L T V L D F F E G S 3.7 0.8 - -
BA060 FLVFDLWEDT F L V F D L W E D T 785.7 - - 7.8
Q16816-2|PHKG1 Isoform 2 of Phosphorylase b 
kinase gamma catalytic chain, skeletal 
muscle/heart isoform
BA061 FTRHDFFESL F T R H D F F E S L 481.7 7.9 - 1.3 Q5THJ4|VP13D Vacuolar protein sorting-associated protein 13D
BA064 VLVADFLEQN V L V A D F L E Q N 772.7 21.5 3.7 1.0 Q9H9S4|CB39L Calcium-binding protein 39-like
BA066 VFVIDSSESI V F V I D S S E S I 3.2 6.7 0.4 -
BA070 VFVIDSSESV V F V I D S S E S V - - - -
BA084 DYLFDFFEHL D Y L F D F F E H L - - - 3.1
BA087 LLVLDIFEDL L L V L D I F E D L 22.9 - - -
IL-2 (pg/ml)Position
ID Human UniProt ID and protein name
Figure S7. Response of Be-specific non-LKGGG CDR3β motif TCRs to biometrical 
analysis naturally-occurring peptides. (A) TR gene segment usage and CDR3 amino acid 
sequence of Be-specific T cell hybridomas expressing TCRs derived from CBD patient BAL 
CD4+ T cells. Amino acids encoded by the TRBD gene and non-germline nucleotides are 
indicated in red bold. The 8845-c1 TCR expresses the LKGGG CDR3β motif with an 
extended CDR3β length. The frequency of these αβTCR pairs relative to the total number of 
αβ pairs obtained is shown. (B) Hybridoma 8845-c1 and 3 non-LKGGG CDR3β T cell 
hybridoma’s responses to a subset of human natural peptides identified from the biometrical 
analyses of the D5E8 PSL results. Peptides were tested at 5 µg/ml in the presence of BeSO4
(75 µM). Green color-coding indicates a positive response, and UniProt protein sources of 

















































































































Figure S8. Investigation of chemokine/Be-specific TCRs potentially cross-reactive to 
plexin A/Be ligands. Eight T cell hybridomas expressing LKGGG CDR3β TCRs specific to 
CCL4/Be were tested for their ability to recognize PLXNA4 and variant CCL4 and PLXNA4 
peptides that differ at the p4 and p6 positions. Peptides (300 ng/ml) were presented by HLA-
DP2 transfected fibroblasts in the presence of BeSO4 (75 μM). All data were normalized to 
hybridoma responses to the wild-type CCL4 peptide. 
Patient TRAV TRAJ Freq Hyb ID
1041 17 C A K L K P H H A S GGS Y I P T F 6 5/103 1041-c7
1435 23/DV6 C A A S T P D E K S T A S K L T F 44 1/99 1435-c5
3421 14/DV4 C A M R E GH QD S S A S K I I F 3 2/105 3421-c4
1234 8-6 C A V D P T F GGGS QGN L I F 42 3/93 1234-c7
3 C A V R D GN S GGY QK V T F 13 2/93 nt1
8133 12-2 C A V K GS D K Y S S A S K I I F 3 1/94 8133-c4
17 C A T A T P A T D N A GN M L T F 39 1/94 nt
13-2 C A E K D P D R Y S S A S K I I F 3 1/94 8133-c4r
8845 12-1 C V V K T P V P L N T GN Q F Y F 49 4/80 8845-c3
13-1 C A A S N P D K GS S A S K I I F 3 4/80 8845-c3r
21 C A V N D R GS T L GR L Y F 18 6/80 8845-c1
10 C V V I R S N D Y K L S F 20 1/80 nt
8-6 C A V S P V N N A R L M F 31 1/80 nt
26-2 C I L L S S G T Y K Y I F 40 1/80 nt
29/DV5 C A V F N A GN N R K L I W F 38 1/80 nt
1 Hybridoma not made.
Deduced CDR3a sequence
Table S1. TRA genes used by T cells expressing the LKGGG CDR3b motif.
Table S2. Biometrical analysis peptides, their protein source and hybridoma 
IL-2 responses to peptide plus Be. 
10mer 1 2 3 4 5 6 7 8 9 10
BA001 NFVVDYYETS N F V V D Y Y E T S 18 1 10 1 2 1 8 388 420 426 365 717 694 651 602 Q8NHW4|CC4L C-C motif chemokine 
4-like
BA002 NFIADYFETS N F I A D Y F E T S 18 1 10 1 2 1 7 431 0 422 393 730 512 665 608 P10147|CCL3 C-C motif chemokine 3
BA003 FFRYDFFERI F F R Y D F F E R I 18 1 10 1 2 2 2 0 0 0 283 0 12 413 0 A0A126LAV1|U7
BA004 LFVIDSFEEL L F V I D S F E E L 18 1 10 4 2 4 0 0 0 0 0 0 0 0 0 Q96MN2|NALP4 NACHT, LRR and 
PYD domains-containing protein 4
BA005 YFRVDFYEAM Y F R V D F Y E A M 12 1 7 1 2 4 6 434 428 0 379 702 733 687 0 Q5I0X7|TTC32 Tetratricopeptide 
repeat protein 32
BA006 ARVFDYFEGA A R V F D Y F E G A 12 1 6 1 1 11 0 0 0 0 3 0 0 0 7 Q9UPN6|SCAF8 Protein SCAF8
BA007 KFVDDLFETI K F V D D L F E T I 12 1 6 25 1 25 0 0 0 0 0 0 3 0 0 Q9HCM2|PLXA4 Plexin-A4
BA008 QLVVDWLESI Q L V V D W L E S I 10 1 6 1 1 3 6 451 302 0 213 621 591 271 0 P57740|NU107 Nuclear pore complex 
protein Nup10
BA009 HFILDFYEKV H F I L D F Y E K V 16 2 8 2 2 8 1 400 0 0 7 0 0 0 0 Q92674|CENPI Centromere protein I
> 1 Cys DCIFDKFECV D C I F D K F E C V 15 2 8 5 2 7 0
Q00005|2ABB Serine/threonine-
protein phosphatase 2A 55 kDa 
regulatory subunit B beta isoform
BA10 NLVDDYFELV N L V D D Y F E L V 13 2 7 3 1 3 0 0 0 0 0 0 0 0 0 P21580|TNAP3 Tumor necrosis factor 
alpha-induced protein 3
No D5 LFKFPFFEAI L F K F P F F E A I 12 2 7 2 2 28 0 Q6ZMT4|KDM7A Lysine-specific 
demethylase 7A
BA011 KFVDDLFETV K F V D D L F E T V 12 2 6 14 1 18 1 7 0 0 1 1 0 330 0 P51805|PLXA3 Plexin-A3
BA012 KSVFDYFEEY K S V F D Y F E E Y 7 2 3 2 1 20 0 0 0 6 2 0 0 0 0 Q07075|AMPE Glutamyl 
aminopeptidase
BA013 ACLKDYFEIQ A C L K D Y F E I Q 5 2 3 2 1 19 0 8 0 0 0 0 0 0 0 Q9UBS8|RNF14 E3 ubiquitin-protein 
ligase
BA014 DFIYDLFEHV D F I Y D L F E H V 17 3 9 4 2 10 4 424 0 0 388 5 488 429 0 Q9HD67|MYO10 Unconventional 
myosin-X
BA015 RFTTDYFEVS R F T T D Y F E V S 14 3 9 3 2 5 1 6 0 0 4 2 3 620 0 Q96PH6|DB118 Beta-defensin 118
BA016 FFRNDFLEVV F F R N D F L E V V 13 3 7 3 2 11 0 0 0 0 148 0 0 73 0
Q8IZE3|PACE1 Protein-associating 
with the carboxyl-terminal domain of 
ezrin
BA017 LFTFDLIESV L F T F D L I E S V 10 3 6 3 1 5 0 141 0 0 0 120 9 0 0 Q92990|GLMN Glomulin




No E8 FLIFDFLLSL F L I F D F L L S L 7 3 3 36 0 NA 0 B0QY84|B0QY84 Phosphatase and 
actin regulator
BA018 KFIVDYSETS K F I V D Y S E T S 4 3 3 3 1 68 6 476 0 197 271 590 278 541 549 P55774|CCL18 C-C motif chemokine 
18
BA019 LFIIDGFEEI L F I I D G F E E I 15 4 8 6 2 6 0 0 0 0 0 0 0 0 0 Q86W25|NAL13 NACHT, LRR and 
PYD domains-containing protein 13
BA020 YLVFDFCEHD Y L V F D F C E H D 15 4 7 7 2 16 0 0 0 0 0 0 0 0 0 P50750|CDK9 Cyclin-dependent 
kinase 9
BA021 NFMADYFETS N F M A D Y F E T S 11 4 7 4 2 9 5 115 0 769 642 702 0 617 663 Q14745|Q14745 C-C motif chemokine 
(Fragment)
BA022 LFVLDYREAH L F V L D Y R E A H 13 5 7 5 2 12 0 0 0 0 0 0 0 0 0 Q8TAV6|Q8TAV6 C6orf134 protein
BA023 YLVADYLEFQ Y L V A D Y L E F Q 12 5 6 5 2 6 0 0 0 0 0 4 1 5 0
Q9H013|ADA19 Disintegrin and 
metalloproteinase domain-containing 
protein 19
BA024 NLKLDLLEAN N L K L D L L E A N 7 5 4 5 1 12 0 0 0 0 0 0 0 0 0 Q8IVI9|NOSTN Nostrin
> 1 Cys CYVQDYLECV C Y V Q D Y L E C V 13 6 7 6 2 7 0 Q9H160|ING2 Inhibitor of growth 
protein 2
BA025 KFIVDYCEKH K F I V D Y C E K H 11 6 8 6 2 22 0 0 0 0 0 0 0 0 0 Q96EK5|KBP KIF1-binding protein
BA026 KFVDDLFETL K F V D D L F E T L 10 6 4 24 1 38 0 8 0 0 0 0 0 0 0 O75051|PLXA2 Plexin-A2
BA027 TYRLDVLEAV T Y R L D V L E A V 9 6 6 6 1 10 0 0 4 0 2 0 5 0 0 O75800|ZMY10 Zinc finger MYND 
domain-containing protein 10
BA028 FRVSDYFEYM F R V S D Y F E Y M 9 6 4 6 1 24 0 0 0 0 26 74 3 5 15 Q96NH3|BROMI Protein broad-
minded
BA029 VFIVDDFESF V F I V D D F E S F 16 7 8 7 2 23 0 0 0 0 0 0 0 3 0 Q99715|COCA1 Collagen alpha-1(XII) 
chain
BA030 WFVYDYSEPA W F V Y D Y S E P A 11 7 5 15 1 17 0 0 0 0 9 0 5 0 0 Q5GH72|XKR7 XK-related protein 7
BA031 WFIGDWLECS W F I G D W L E C S 10 7 6 7 1 9 0 0 0 0 0 0 0 0 0
Q9UKP5|ATS6 A disintegrin and 
metalloproteinase with 
thrombospondin motifs 6
BA032 QCIADFLEYM Q C I A D F L E Y M 9 7 4 13 1 14 0 111 5 0 71 153 91 7 0 P52789|HXK2 Hexokinase-2
BA033 SFVTDIFERI S F V T D I F E R I 9 7 4 36 1 50 0 0 0 0 0 0 0 0 0 Q96A08|H2B1A Histone H2B type 1-A
BA034 LCLIDYYESK L C L I D Y Y E S K 14 8 9 8 2 16 0 0 0 0 15 11 0 0 0 Q8NHQ1|CEP70 Centrosomal protein 
of 70 kDa
BA035 QLGFDFFEAS Q L G F D F F E A S 13 8 7 8 2 34 0 0 0 0 0 0 0 0 0 P20337|RAB3B Ras-related protein 
Rab-3B
BA036 SFVNDIFERI S F V N D I F E R I 7 8 3 47 1 58 0 0 0 5 0 0 0 0 0 P57053|H2BFS Histone H2B type F-S


















































10mer 1 2 3 4 5 6 7 8 9 10
BA037 YFVLDTSESV Y F V L D T S E S V 15 9 7 9 2 98 0 1 0 0 3 1 0 0 1 P12110|CO6A2 Collagen alpha-2(VI) 
chain
BA038 FIKDDYLETI F I K D D Y L E T I 10 9 6 14 2 52 0 0 0 0 0 0 1 1 0 Q9BQI5|SGIP1 SH3-containing GRB2-
like protein 3-interacting protein 1
BA039 QCKFDLLEEL Q C K F D L L E E L 8 9 6 9 1 18 0 0 0 0 0 0 0 0 0 Q8WWC4|MAIP1 m-AAA protease-
interacting protein 1, mitochondrial
BA040 DNVKDYFECS D N V K D Y F E C S 7 9 3 9 1 72 0 15 0 0 5 5 4 3 3 Q07343|PDE4B cAMP-specific 3',5'-
cyclic phosphodiesterase 4B
BA041 KIIADIFEYT K I I A D I F E Y T 4 9 3 9 1 83 1 5 0 666 0 0 4 2 0 P22033|MUTA Methylmalonyl-CoA 
mutase, mitochondrial
No E8 SCVVDYFLGH S C V V D Y F L G H 2 9 2 9 0 NA 0 Q9H857|NT5D2 5'-nucleotidase 
domain-containing protein 2
> 1 Cys ICCFDSFEYV I C C F D S F E Y V 18 10 10 10 2 13 0 Q96S79|RSLAB Ras-like protein family 
member 10B
No E8 LCVLDYFIKL L C V L D Y F I K L 12 10 6 10 1 14 0 P06400|RB Retinoblastoma-
associated protein
BA042 LCVSDPFELT L C V S D P F E L T 8 10 4 15 1 29 0 0 0 0 0 0 0 0 0 Q6ZMU1|C3P1 Putative protein C3P1
BA043 SVVRDYFEGS S V V R D Y F E G S 7 10 3 10 1 53 0 15 0 0 1 2 3 0 0 Q9NRD9|DUOX1 Dual oxidase 1
No D5 TIIYSYLESL T I I Y S Y L E S L 5 10 2 31 0 NA 0 Q7Z5P4|DHB13 17-beta-
hydroxysteroid dehydrogenase 13
BA044 TFPIDFFEHN T F P I D F F E H N 14 11 8 11 2 15 0 44 0 0 0 0 2 0 0 Q5T4S7|UBR4 E3 ubiquitin-protein 
ligase UBR4
BA045 ICVADPFEVT I C V A D P F E V T 10 11 5 12 1 32 0 0 0 0 0 0 0 0 0 P01024|CO3 Complement C3
BA046 IIDIDYFEGL I I D I D Y F E G L 9 11 6 11 1 21 0 13 0 0 0 0 0 0 0 O95196|CSPG5 Chondroitin sulfate 
proteoglycan 5
No D5 FFIFYYLEGT F F I F Y Y L E G T 6 11 2 19 0 NA 0 O75175|CNOT3 CCR4-NOT 
transcription complex subunit 3
BA047 KLSLDYFEKQ K L S L D Y F E K Q 4 11 4 11 1 96 0 10 0 0 0 0 2 0 0 Q9NQZ6|ZC4H2 Zinc finger C4H2 
domain-containing protein
BA048 NYIYDLLEEV N Y I Y D L L E E V 9 12 5 12 1 22 1 406 0 0 86 0 11 25 0 Q02241|KIF23 Kinesin-like protein 
KIF23
No D5 FLVFFFFERV F L V F F F F E R V 7 12 2 29 0 NA 0 Q8N7Y7|Q8N7Y7 cDNA FLJ40209 fis, 
clone TESTI2020999
BA049 SFVNDVFEQL S F V N D V F E Q L 7 12 3 49 1 81 0 0 0 4 0 0 0 0 0 L0R4T3|L0R4T3 Histone H2B
BA050 GVIYDLLECL G V I Y D L L E C L 5 12 3 29 1 57 0 0 0 0 0 0 0 0 0 Q9NV88|INT9 Integrator complex 
subunit 9
BA051 FFVLDTSESV F F V L D T S E S V 12 13 4 17 0 NA 0 0 0 0 0 0 0 0 0 P12109|CO6A1 Collagen alpha-1(VI) 
chain
BA052 GFVIDYTENP G F V I D Y T E N P 8 13 4 13 1 56 0 12 0 0 0 2 0 0 0 Q7Z408|CSMD2 CUB and sushi 
domain-containing protein 2
No E8 SLVFDYYNSV S L V F D Y Y N S V 7 13 2 22 0 NA 0 Q7Z3S7|CA2D4 Voltage-dependent 
calcium channel subunit alpha-2/delta-




BA054 EKKIDYFERA E K K I D Y F E R A 3 13 3 13 1 64 0 15 0 0 0 0 0 2 0 Q14152|EIF3A Eukaryotic translation 
initiation factor 3 subunit A
BA055 NCVTDEFEEG N C V T D E F E E G 3 13 1 13 0 NA 0 14 0 3 4 4 4 3 0 Q9UL15|BAG5 BAG family molecular 
chaperone regulator 5
BA056 LDILDYYEAS L D I L D Y Y E A S 7 14 4 14 1 59 0 0 0 0 0 0 0 0 0 P78352-2|DLG4 Isoform 2 of disks 
large homolog 4
No E8 TYVLDYLKST T Y V L D Y L K S T 4 14 2 51 0 NA 0 Q6IE37|OVOS1 Ovostatin homolog 1
No D5 STVFLYFESV S T V F L Y F E S V 4 14 2 76 0 NA 0 Q9HC24|LFG4 Protein lifeguard 4
BA057 KIKEDYFEKH K I K E D Y F E K H 3 14 3 14 1 83 0 9 0 0 0 0 2 2 0 Q9H3M9|ATX3L Ataxin-3-like protein
> 1 Cys DCIFDKFECA D C I F D K F E C A 11 15 5 18 1 26 0
Q9Y2T4|2ABG Serine/threonine-
protein phosphatase 2A 55 kDa 
regulatory subunit B gamma isoform
BA058 LTVLDFFEGS L T V L D F F E G S 9 15 4 15 1 52 0 0 0 0 0 0 0 0 0 Q9NRD8|DUOX2 Dual oxidase 2
BA059 QLTADYFEKT Q L T A D Y F E K T 8 15 8 15 2 30 0 11 0 0 0 0 0 0 0
Q9Y6B7|AP4B1 AP-4 complex subunit 
beta-1
BA060 FLVFDLWEDT F L V F D L W E D T 7 15 4 15 1 23 3 432 0 0 398 73 673 0 0
Q16816-2|PHKG1 Isoform 2 of 
Phosphorylase b kinase g catalytic 
chain, skeletal muscle/heart isoform
BA061 FTRHDFFESL F T R H D F F E S L 7 15 2 76 0 NA 0 0 0 0 82 0 1 156 0 Q5THJ4|VP13D Vacuolar protein 
sorting-associated protein 13D
BA062 TLLFDFLEVC T L L F D F L E V C 5 15 4 15 1 24 0 0 0 3 0 3 0 0 0 Q53GS7|GLE1 Nucleoporin GLE1
BA063 PPHIDYFEEI P P H I D Y F E E I 5 15 3 15 1 74 0 10 0 0 0 0 0 0 0
Q9UBE8|NLK Serine/threonine-protein 
kinase NLK
> 1 Cys DCIFDKFECC D C I F D K F E C C 9 16 5 35 1 35 0
Q66LE6|2ABD Serine/threonine-
protein phosphatase 2A 55 kDa 
regulatory subunit B delta isoform
BA064 VLVADFLEQN V L V A D F L E Q N 7 16 3 16 1 19 0 198 0 0 1 2 3 0 0 Q9H9S4|CB39L Calcium-binding 
protein 39-like
BA065 FLLTDYFEED F L L T D Y F E E D 4 16 4 16 1 71 2 8 0 28 17 478 4 0 683 Q8IVI9|NOSTN Nostrin
BA066 VFVIDSSESI V F V I D S S E S I 10 17 2 33 0 NA 0 0 0 0 0 0 0 0 0 P12110|CO6A2 Collagen alpha-2(VI) 
chain
No D5 LFIFALFETI L F I F A L F E T I 6 17 3 34 0 NA 0 Q8NHS3|MFSD8 Major facilitator super- 
family domain-containing protein 8





















































10mer 1 2 3 4 5 6 7 8 9 10
BA067 VKIKDYFEKL V K I K D Y F E K L 5 17 3 22 1 46 0 12 0 0 0 0 2 2 2 P04114|APOB Apolipoprotein B-100
BA068 HFVCDNFEQF H F V C D N F E Q F 5 17 3 58 1 88 0 11 0 0 4 4 2 4 2 A0A126LAV1|A0A126LAV1 U7
BA069 PHREDYFEPI P H R E D Y F E P I 4 17 2 17 1 93 0 9 0 0 0 0 1 2 0 Q69YN4|VIR Protein virilizer homolog
No E8 FLKLDYFQNL F L K L D Y F Q N L 2 17 1 17 0 NA 0 Q5VWM4|PRAM8 PRAME family 
member 8
BA070 VFVIDSSESV V F V I D S S E S V 11 18 3 21 0 NA 0 0 0 0 0 0 0 0 0 Q2UY09|COSA1 Collagen alpha-
1(XXVIII) chain
BA071 ILPNDYFEIV I L P N D Y F E I V 7 18 5 18 1 34 0 11 0 0 0 0 3 0 0 Q9NVV9|THAP1 THAP domain-
containing protein 1
BA072 VLLHDFLEDV V L L H D F L E D V 4 18 3 18 1 26 0 0 0 0 0 0 0 0 0 Q6ZV50|RFX8 DNA-binding protein 
RFX8
No D5 LLVYSYFEKS L L V Y S Y F E K S 4 18 2 18 0 NA 0 M0R1H8|M0R1H8 Zinc finger protein 
431 (Fragment)
BA073 VCILDVYENM V C I L D V Y E N M 4 18 3 51 1 51 0 0 0 0 0 0 0 0 0 Q16644|MAPK3 MAP kinase-activated 
protein kinase 3
BA074 KLILDIFEYE K L I L D I F E Y E 2 18 1 18 0 NA 0 9 0 0 0 0 0 0 0 Q8IZF2|AGRF5 Adhesion G protein-
coupled receptor F5
BA075 VIIFDALEQL V I I F D A L E Q L 7 19 4 19 1 39 0 1 0 0 1 0 108 3 0 Q9ULI1|NWD2 NACHT and WD repeat 
domain-containing protein 2
BA076 PFSFDFFEDP P F S F D F F E D P 7 19 3 19 1 47 3 707 0 0 382 31 0 359 0 O75190|DNJB6 DnaJ homolog 
subfamily B member 6
BA077 FCFVDLYEAQ F C F V D L Y E A Q 5 19 3 26 1 40 0 0 0 5 0 0 0 0 0 V9GZL3|V9GZL3 GBP
> 1 Cys QCCIDNFEEI Q C C I D N F E E I 4 19 2 19 1 80 0 Q96T49|PP16B Protein phosphatase 
1 regulatory inhibitor subunit 16B
BA078 LLLIDFYEKT L L L I D F Y E K T 8 20 5 20 1 28 0 14 3 0 0 0 0 0 0 Q7Z6Z7|HUWE1 E3 ubiquitin-protein 
ligase HUWE1
BA079 TCIKDEFEKI T C I K D E F E K I 7 20 2 37 1 39 0 0 0 0 0 0 0 0 0 A0A126LAY5|A0A126LAY5 
Glycoprotein B
No E8 LYIIDFFIAL L Y I I D F F I A L 6 20 3 25 1 86 0 Q9P241|AT10D Probable 
phospholipid-transporting ATPase VD
BA080 GLLIDYFEKK G L L I D Y F E K K 4 20 4 20 1 40 0 12 0 0 0 0 1 0 0 O00237|RN103 E3 ubiquitin-protein 
ligase RNF103
No D5E8 LFVFNFFFWV L F V F N F F F W V 4 20 2 20 0 NA 0 A1L157|TSN11 Tetraspanin-11
BA081 QLLVDFWEAQ Q L L V D F W E A Q 3 20 3 20 1 31 1 74 0 0 0 383 0 0 0 Q969F9|HPS3 Hermansky-Pudlak 
syndrome 3 protein
BA082 LEEGDYFEAI L E E G D Y F E A I 3 20 3 20 1 51 0 8 0 0 0 0 0 0 0 Q96JQ2|CLMN Calmin
BA083 SCVEDGFEGD S C V E D G F E G D 3 20 1 26 0 NA 0 11 0 0 0 7 0 0 112 P42684|ABL2 Abelson tyrosine-
protein kinase 2
BA084 DYLFDFFEHL D Y L F D F F E H L 11 21 5 30 2 36 1 1 0 0 203 94 0 0 0 Q9NPP4|NLRC4 NLR family CARD 
domain-containing protein 4
BA085 TCPVDPFEAQ T C P V D P F E A Q 1 21 1 21 0 NA 0 13 0 0 2 1 1 0 2 P49757|NUMB Protein numb homolog
No D5 FFIFLLLEAV F F I F L L L E A V 7 22 3 22 0 NA 0 L0R8E0|L0R8E0 Alternative protein 
RPIA
BA086 LFYGDFLEQL L F Y G D F L E Q L 5 22 4 22 1 32 0 0 0 7 0 0 0 0 0 H7C1G2|H7C1G2 Cordon-bleu protein-
like 1 (Fragment)
No E8 FIILDWFHAI F I I L D W F H A I 4 22 1 43 0 NA 0 Q53QZ3|RHG15 Rho GTPase-
activating protein 15
> 1 Cys ACLVDFFTNC A C L V D F F T N C 1 22 1 22 0 NA 0 P49902|5NTC Cytosolic purine 5'-
nucleotidase
BA087 LLVLDIFEDL L L V L D I F E D L 12 23 7 23 2 25 0 145 0 0 0 0 0 0 0 Q92911|SC5A5 Sodium/iodide 
cotransporter
BA088 LIILDTLEIV L I I L D T L E I V 5 23 4 23 1 37 0 0 0 2 1 0 0 0 0 Q96N67|DOCK7 Dedicator of 
cytokinesis protein 7
BA089 WLYFDALECL W L Y F D A L E C L 5 23 3 23 1 48 0 0 0 0 0 0 0 0 0 P22314|UBA1 Ubiquitin-like modifier-
activating enzyme 1




BA091 HKISDYFEYQ H K I S D Y F E Y Q 3 23 3 23 1 57 0 16 0 0 0 2 0 3 0 Q9UKI8|TLK1 Serine/threonine-protein 
kinase tousled-like 1
No E8 FLKLDYCRSN F L K L D Y C R S N 3 23 1 29 0 NA 0 A0A126GW04|A0A126GW04 
Olfactory receptor
BA092 LFIMDGFEQL L F I M D G F E Q L 5 24 3 44 1 44 0 0 0 0 0 0 0 0 0 Q7RTR0|NALP9 NACHT, LRR and 
PYD domains-containing protein 9
BA093 FLLLDALEAA F L L L D A L E A A 4 24 3 24 1 45 0 0 0 0 0 0 0 0 0 B2RA97|B2RA97 HemK 
methyltransferase family member 2
BA094 ETIKDYFEAR E T I K D Y F E A R 2 24 2 24 0 NA 0 14 0 0 0 0 1 0 0 Q99549|MPP8 M-phase 
phosphoprotein 8
BA095 VFQQDCFEYF V F Q Q D C F E Y F 2 24 2 24 0 NA 0 14 0 0 0 0 0 0 0 O15397|IPO8 Importin-8
BA096 NWIGDYFEKA N W I G D Y F E K A 6 25 6 25 2 42 0 10 0 0 0 0 0 0 0 Q8NCM8|DYHC2 Cytoplasmic dynein 2 
heavy chain 1
BA097 FLTYDICEVS F L T Y D I C E V S 5 25 3 25 1 44 0 0 0 0 0 0 0 0 0 Q8IY18|SMC5 Structural maintenance 
of chromosomes protein 5
BA098 HFSEDYLECV H F S E D Y L E C V 4 25 2 25 1 49 0 0 0 3 2 0 0 2 0 Q9Y625|GPC6 Glypican-6
BA099 LTRLDFLEWP L T R L D F L E W P 2 25 2 25 0 NA 0 16 0 0 1 2 2 1 0 B4DKJ8|B4DKJ8 Oxysterol-binding 
protein
BA100 KLLLDTFEYQ K L L L D T F E Y Q 1 25 1 25 0 NA 0 14 4 8 2 4 3 2 2 Q7Z7K6|CENPV Centromere protein V




















































Table S3. Mean EC50 values (nM) of two experiments for 4 hybridomas
to CCL4 length variant peptides. 
8845-c3 8845-c3r 8133-c4 8133-c4r
RNFVVDYYETS 11-mer 180.5 173.5 198.5 61.8
NFVVDYYETSS 11-mer 318.3 85.9 160.4 56.1
NFVVDYYETS 10-mer 164.6 106.5 156.0 45.3
FVVDYYETSS 10-mer 113.5 43.1 61.4 16.3
NFVVDYYET 9-mer 352.1 171.7 376.6 100.6
FVVDYYETS 9-mer 79.1 65.7 62.7 19.1
NFVVDYYE 8-mer 448.7 573.2 468.4 180.3
FVVDYYET 8-mer 212.7 167.6 183.9 49.2
FVVDYYE 7-mer 474.2 1189.0 429.0 222.2
FVVDYY 6-mer nd
1 nd nd nd 
VVDYYETS 8-mer nd nd nd nd
 1 nd: not determined due to low responses to peptides at concentrations used.
EC50 values (nM)
CCL4 Peptide Length
Table S4. Mean EC50 values (nM) of two experiments for 4 hybridomas
to CCL3 length variant peptides. 
8845-c3 8845-c3r 8133-c4 8133-c4r
NFIADYFETSS 11-mer 74.2 neg1 114.4 43.1
NFIADYFETS 10-mer 99.4 neg 114.6 49.7
FIADYFETSS 10-mer 46.9 neg 58.4 30.8
FIADYFETS 9-mer 77.6 neg 76.3 52.6
FIADYFET 8-mer 118.7 neg 142.8 105.6














BAL T cell lines4
1041 62 *02:01/*04:01 22 yrs, 9 mo 52.5 ABNL5 ABNL
1435 35 *02:01/*17:01 < 1 month 78.0 ABNL NL
3421 56 *02:01/*04:01 < 1 month 58.1 ABNL NL
Ex vivo BAL T cells4
1234 54 *02:01/*13:01 3 yrs, 7 mo 2.7 ABNL ABNL
8133 62 *02:01/*04:02 2 yrs 59.0 ABNL NL
 8845 55 *01:01/*02:01 < 1 month 14.3 ABNL ABNL
6092 68 *02:01/*04:02 7 yrs, 3 mos 5.6 NL NL
1 Six nonhispanic males and one hispanic female (1234).
2 Percentage of collected BAL cells that are lymphocytes.
3 LPT, Lymphocyte Proliferation Test is considered abnormal if two or more of six
  conditions tested are greater than a mean stimulation index of 2.5.
4 Number of CD4+ T cells sorted: BAL T cell lines = 143; ex vivo BAL T cells = 191.
5 ABNL - abnormal result; NL - normal result. 
Table S5. Demographics of CBD study population.
